Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 5/20 | 0.62 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 6/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12112408 | 0.79 | ENPP3 (0.96) | ENPP3ENPP1TP53POLBTHRB | |
| Ammonia Solution, Strong SCHEMBL28862464 | 0.77 | ENPP3 (0.92) | ENPP3ENPP1TP53POLBTHRB | |
| SCHEMBL2056109 | 0.76 | ENPP3 (0.69) | ENPP3ENPP1TP53POLBTHRB | |
| SCHEMBL6986241 | 0.76 | ENPP3 (0.69) | ENPP3ENPP1TP53POLBTHRB | |
| SCHEMBL8117354 | 0.76 | ENPP3 (0.69) | ENPP3ENPP1TP53POLBTHRB | |
| SCHEMBL24415640 | 0.76 | ENPP3 (0.69) | ENPP3ENPP1TP53POLBTHRB | |
| SCHEMBL1169116 | 0.76 | ENPP3 (0.69) | ENPP3ENPP1TP53POLBTHRB | |
| SCHEMBL2265105 | 0.75 | ENPP3 (0.68) | ENPP3ENPP1TP53POLBTHRB | |
| SCHEMBL1106600 | 0.75 | IRAK4 (0.39) | ENPP3ENPP1 | |
| SCHEMBL201523 | 0.73 | ENPP3 (0.96) | ENPP3ENPP1TP53POLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | ENPP3 1266/4885ENPP1 1005/4885TP53 3707/4885 |
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM4 | ENPP3 1766/4885ENPP1 1139/4885TP53 2420/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | ENPP3 1266/4885ENPP1 1005/4885TP53 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.